FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, announces that it has been listed for trading on the OTCQB® Market exchange in the United States under the symbol “PRTX.”
“Admission to the OTCQB exchange is part of our long-term strategy to re-introduce the company to a broader range of institutional and retail investors in the U.S.”
“Trading on the OTCQB will expand Protalex’s presence among the investing public and will provide our existing shareholders with a transparent trading platform,” stated Arnold Kling, President and Chief Executive Officer of Protalex. “Admission to the OTCQB exchange is part of our long-term strategy to re-introduce the company to a broader range of institutional and retail investors in the U.S.”
Protalex had previously traded on the Pink Sheet under trading symbol “PRTX.”
About Protalex, Inc.
Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP). Protalex’s lead product, PRTX-100, is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The safety, tolerability and pharmacokinetics of PRTX-100 have been characterized in five clinical studies. In two Phase 1b clinical trials in adult patients with active RA, PRTX-100 was generally safe and well tolerated at all dose levels, and at certain higher doses, more patients showed improvement in measures of RA disease activity than did patients at the lower dose or placebo cohorts.
Forward-Looking Statements
Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company’s actual operating or clinical results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expects,” “expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,” “plan,” to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with Securities and Exchange Commission.
Contacts
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
Help employers find you! Check out all the jobs and post your resume.
